Reata Pharmaceuticals, Inc. (RETA) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in Plano, TX, United States. Der aktuelle CEO ist J. Warren Huff.
RETA hat IPO-Datum 2016-05-26, 321 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Market, eine Marktkapitalisierung von $6.57B.
Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for serious and life-threatening diseases. The company's lead programs include bardoxolone methyl in Phase 3 trials for chronic kidney disease associated with Alport syndrome and pulmonary arterial hypertension, omaveloxolone in Phase 2 development for Friedreich's ataxia, and multiple Phase 2 programs targeting various forms of chronic kidney disease. Reata also has investigational compounds RTA 901 for neurological diseases and RTA 1701 for autoimmune, inflammatory, and fibrotic conditions, along with commercial access to bardoxolone for autosomal dominant polycystic kidney disease. The company has established strategic partnerships with Kyowa Kirin for bardoxolone development across Asia-Pacific markets and with AbbVie for next-generation Nrf2 activators in non-renal indications. Based in Plano, Texas, Reata was incorporated in 2002 and focuses on addressing unmet medical needs through targeted therapeutic innovation.
